Search Result

Isoforms Recommended:	AMPA Receptor

Results for "

AMPA receptor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (18) c-Met/HGFR (2) Calcium Channel (8) CaMK (1) Carbonic Anhydrase (6) Cytochrome P450 (2) Endogenous Metabolite (16) Ferroptosis (16) GABA Receptor (6) Glutaminase (2) iGluR (123) Isotope-Labeled Compounds (6) Lipoxygenase (1) LPL Receptor (1) mGluR (1) mTOR (1) Phosphatase (1) PKC (1) Potassium Channel (6) Sodium Channel (7) Somatostatin Receptor (2) TRP Channel (2) Tyrosinase (2)
By Research Areas:	Cancer (7) Inflammation/Immunology (1) Metabolic Disease (3) Neurological Disease (127)

135

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-136275

AMPA receptor modulator-2	iGluR	Others
AMPA receptor modulator-2 (Example 134) is a **AMPA receptor modulator, with a pIC₅₀** of 10.1 for TARPγ8 dependent AMPA receptor . pIC₅₀ = -lgIC₅₀.

HY-122150

AMPA receptor modulator-3	iGluR	Neurological Disease
AMPA receptor modulator-3 is an allosteric *AMPA* receptor modulator (EC₅₀: 4.4 μM). AMPA receptor modulator-3 can be used in the research of mammalian nervous system, such as learning and memory .

HY-161090

AMPA receptor modulator-7	iGluR	Neurological Disease
AMPA receptor modulator-7 (compound 36) is a modulator of **AMPA receptor*. AMPA* receptor modulator-7 has oral activity and can penetrate the blood-brain barrier .

HY-149975

AMPA receptor modulator-4	iGluR	Neurological Disease
AMPA receptor modulator-4, a 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide (BTD), is an orally active positive allosteric modulator of the AMPA receptors (AMPAR PAMs). AMPA receptor modulator-4 can cross the blood-brain barrier. AMPA receptor modulator-4 increases the cognition performance and improves working memory performance in mice .

HY-154798

AMPA receptor modulator-5	iGluR	Neurological Disease
AMPA receptor modulator-5 (Example 217) is an **AMPA receptor** modulator. AMPA receptor modulator-5 can be used for research of neurological disease .

HY-155628

AMPA receptor modulator-6	iGluR	Others
AMPA receptor modulator-6 is an *AMPA* receptor positive allosteric modulator (PAM). AMPA receptor modulator-6 can be used in the study of neurological diseases .

HY-136905

AMPA receptor antagonist-2	iGluR	Others
AMPA receptor antagonist-2 (example 23) is an **AMPA receptor** antagonist .

HY-145959

AMPA receptor antagonist-3	iGluR	Neurological Disease
AMPA receptor antagonist-3 is an **AMPA receptor** antagonist extracted from patent US20070027143A1. AMPA receptor antagonist-3 can be used for the research of central nervous system disorders .

HY-112699

AMPA receptor modulator-1	iGluR	Neurological Disease
AMPA receptor modulator-1 is a potent, orally active and selective AMPAR regulatory protein TARP γ-8 negative modulator with a pIC₅₀ of 9.7, more selective over GluA1/γ-2 (pIC₅₀=5) .

HY-103235

NPEC-caged-(S)-AMPA	iGluR	Neurological Disease
NPEC- caged-(S)-AMPA, a caged neurotransmitter analog, is a NPEC photoprotecting group caged the (S)-AMPA (HY-100815A) to make caged ligands specific for glutamate receptor sub-types. NPEC- caged-(S)-AMPA selectively activates **AMPA receptor** .

HY-145761

AMPA-IN-1	iGluR	Neurological Disease
AMPA-IN-1 is a potent inhibitor of *AMPA* receptor. AMPA receptors are receptors that are widely expressed in the brain, and play a central role in the regulation of fast excitatory synaptic transmission and synaptic plasticity. AMPA-IN-1 has the potential for the research of various central diseases including epilepsy (extracted from patent WO2017082288A1, compound 14) .

HY-101165

Cyclothiazide	iGluR	Neurological Disease
Cyclothiazide, a positive allosteric modulator of **AMPA receptors*, is used frequently to block the desensitization of both native and heterologously expressed AMPA* receptors. Cyclothiazide is known to produce a fast inhibition of AMPA receptor desensitization and a much slower potentiation of the AMPA current .

HY-101165R

Cyclothiazide (Standard)	iGluR	Neurological Disease
Cyclothiazide (Standard) is the analytical standard of Cyclothiazide. This product is intended for research and analytical applications. Cyclothiazide, a positive allosteric modulator of **AMPA receptors*, is used frequently to block the desensitization of both native and heterologously expressed AMPA* receptors. Cyclothiazide is known to produce a fast inhibition of AMPA receptor desensitization and a much slower potentiation of the AMPA current .

HY-106039

LY 215490	Others	Neurological Disease
LY 215490 is a selective, competitive **AMPA receptor antagonist against AMPA, CGSl9755 and kainate with IC₅₀** values of 4.8, 26.4 and 247 μM, respectively. LY 215490 shows neuroprotective effects in focal ischaemia .

HY-120811

PF-04701475	iGluR	Neurological Disease
PF-04701475 is a potent **AMPA receptor potentiator with an EC₅₀** of 123 nM. PF-04701475 can be used for the study of neurological disorders .

HY-122164

LY-503430	iGluR	Neurological Disease
LY-503430 is an orally active **AMPA receptor** positive allosteric modulator (PAM). LY-503430 can be used for the study of Parkinson's disease .

HY-107606

UBP301	iGluR	Neurological Disease
UBP301 is a potent and selective antagonist of kainate receptor with IC₅₀ and K_D of 164 μM and 5.94 μM, respectively. UBP301 has ∼30-fold selectivity of kainate receptor over AMPA receptor. UBP301 is the derivative of willardiine .

HY-107606A

UBP301 hydrochloride	iGluR	Neurological Disease
UBP301 hydrochloride is a potent and selective antagonist of kainate receptor with IC₅₀ and K_D of 164 μM and 5.94 μM, respectively. UBP301 hydrochloride has ～30-fold selectivity of kainate receptor over AMPA receptor. UBP301 hydrochloride is the derivative of willardiine .

HY-10933

CX516 2 Publications Verification BDP 12	iGluR	Neurological Disease
CX516 (BDP 12) is an ampakine and acts as an *AMPA* receptor positive allosteric modulator for the research of Alzheimer's disease, schizophrenia and mild cognitive impairment (MCI) .

HY-15078

NS1219 (R)-SPD502	iGluR	Neurological Disease
NS1219 ((R)-SPD502) is the isomer of NS 1209 HY-15074. NS1209 is a selective **AMPA receptor** antagonist with neuroprotective activity. NS1209 can be used for the research of stroke, neuropathic pain and epilepsy .

HY-118424

JNJ-55511118	iGluR	Neurological Disease
JNJ-55511118 is a highly potent, reversible, and selective **AMPA receptor** inhibitor selective for TARP-γ8. JNJ-55511118 fully displaces the radioligand (20 nM) with the K_i of 26 nM in competition binding experiments. JNJ-55511118 is a tool molecule with potential therapeutic utility as an anticonvulsant or neuroprotectant .

HY-139897

CX 717	iGluR	Neurological Disease
CX 717 is a positive allosteric modulator of **AMPA receptor**. Antidepressant-like effect. CX 717 can be used for the research of adult attention deficit hyperactivity disorder (ADHD) .

HY-120020

LY-395153	Others	Others
LY-395153 is an AMPA receptor enhancer with the activity of binding to AMPA receptors. LY-395153 can bind to natural and recombinant AMPA receptors, and its binding is affected by AMPA receptor agonists and can be competitively or non-competitively inhibited by some compounds. It is a useful probe for marking unique regulatory sites of AMPA receptors.

HY-100815A

(S)-AMPA L-AMPA	iGluR	Neurological Disease
(S)-AMPA (L-AMPA), an active S-enantiomer of AMPA, is a potent and selective **AMPA receptor** agonist .

HY-108599

DCP-LA 4 Publications Verification FR236924	PKC CaMK Phosphatase Apoptosis	Neurological Disease
DCP-LA (FR236924), a linoleic acid derivative, selectively and directly activates PKCε. DCP-LA activates Ca( ²⁺)/calmodulin-dependent protein kinase II (CaMKII) and inhibits protein phosphatase-1 (PP-1) to stimulate AMPA receptor exocytosis. DCP-LA inhibits activation of caspase-3/-9 and protects neurons at least in part from oxidative stress-induced apoptosis .

HY-100815

(R)-AMPA	Others	Neurological Disease
(R)-AMPA is an inactive AMPA receptor ligand that inhibits the release of excitatory amino acids from neurons. (R)-AMPA is inactive in experiments that enhance the release of [3H]D-aspartate induced by electrical stimulation. (R)-AMPA is inhibited by competitive and noncompetitive AMPA receptor selective antagonists in response to AMPA and glutamate .

HY-124906

JAMI1001A	iGluR	Neurological Disease
JAMI1001A is a positive allosteric modulator of **AMPA receptor*. JAMI1001A efficaciously modulates AMPA* receptor deactivation and desensitization of both flip and flop receptor isoforms .

HY-12509

PEPA	iGluR	Neurological Disease
PEPA is an allosteric modulator of AMPA receptors; binds to the GluA2o and GluA3o LBDs and can be utilized as an indicator of AMPA receptor heterogeneity.

HY-100815B

(RS)-AMPA (±)-AMPA	iGluR	Neurological Disease
(RS)-AMPA ((±)-AMPA) is a glutamate analogue and a potent and selective excitatory neurotransmitter L-glutamic acid agonist. (RS)-AMPA does not interfere with binding sites for kainic acid or NMDA receptors .

HY-100815D

(RS)-AMPA monohydrate (±)-AMPA monohydrate	iGluR	Neurological Disease
(RS)-AMPA ((±)-AMPA) monohydrate is a glutamate analogue and a potent and selective excitatory neurotransmitter L-glutamic acid agonist. (RS)-AMPA monohydrate does not interfere with binding sites for kainic acid or NMDA receptors .

HY-129030

BDZ-g	iGluR	Neurological Disease
BDZ-g is a potent, selective antagonist of *AMPA* receptor. BDZ-g has the potential for the research of various neurological disorders involving excessive activity of AMPA receptors .

HY-100815E

(RS)-AMPA hydrochloride (±)-AMPA hydrochloride	iGluR	Neurological Disease
(RS)-AMPA ((±)-AMPA) hydrochloride is a glutamate analogue and a potent and selective excitatory neurotransmitter L-glutamic acid agonist. (RS)-AMPA hydrobromide does not interfere with binding sites for kainic acid or NMDA receptors .

HY-100815C

(RS)-AMPA hydrobromide (±)-AMPA hydrobromide	iGluR	Neurological Disease
(RS)-AMPA ((±)-AMPA) hydrobromide is a glutamate analogue and a potent and selective excitatory neurotransmitter L-glutamic acid agonist. (RS)-AMPA hydrobromide does not interfere with binding sites for kainic acid or NMDA receptors .

HY-12506A

Naspm trihydrochloride 5+ Cited Publications 1-Naphthylacetyl spermine trihydrochloride	iGluR	Neurological Disease
Naspm trihydrochloride (1-Naphthylacetyl spermine trihydrochloride), a synthetic analogue of Joro spider toxin, is a calcium permeable AMPA (CP-AMPA) receptors antagonist.

HY-12506

Naspm 5+ Cited Publications 1-Naphthylacetyl spermine	iGluR	Neurological Disease
Naspm (1-Naphthyl acetyl spermine), a synthetic analogue of Joro spider toxin, is a calcium permeable AMPA (CP-AMPA) receptors antagonist.

HY-112781

Pesampator PF-04958242	iGluR	Neurological Disease
Pesampator (PF-04958242) is a potent and highly selective positive allosteric modulator of **AMPA receptor** (an AMPA potentiator) with an EC₅₀ of 310 nM and a K_i of 170 nM .

HY-15070

YM 900	iGluR	Neurological Disease
YM 900 is an **AMPA receptor** antagonist .

HY-100785

gamma-DGG γDGG; γ-D-Glutamylglycine	iGluR	Neurological Disease
gamma-DGG is a competitive **AMPA receptor** blocker.

HY-101216

Org-26576	iGluR	Neurological Disease
Org-26576 is a *AMPA* receptor positive allosteric modulator.

HY-10934

Mibampator LY451395	iGluR	Neurological Disease
Mibampator (LY451395) is a potent and highly selective potentiator of the AMPA receptors.

HY-118814

YM928	Others	Neurological Disease
YM928 is an orally active and noncompetitive α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist. YM928 inhibits **AMPA receptor**-mediated toxicity in primary rat hippocampal cultures with an IC₅₀ value of 2 μM. YM928 blocks AMPA-induced intracellular calcium influx with an IC₅₀ value of 3 μM and antagonizes AMPA-induced inward currents with an IC₅₀ value of 1 μM. YM928 is promising for research of neurological disorders .

HY-12499

(S)-Willardiine (-)-Willardiine	iGluR	Neurological Disease
(S)-Willardiine is a potent agonist of AMPA/kainate receptors with EC50 of 44.8 uM.

HY-10937

Farampator CX-691; Org24448	iGluR	Neurological Disease
Farampator (CX-691;Org24448) is an *AMPA* receptor positive modulator.

HY-108707

LY3130481 1 Publications Verification	iGluR	Neurological Disease
LY3130481 is an orally available *AMPA* receptor antagonist, selectively inhibiting the IC₅₀ value of AMPA/TARP γ-8 at 65 nM. LY3130481 has anticonvulsant, antiepileptic, and pain-relieving effects .

HY-14451

PF-4778574	iGluR	Neurological Disease
PF-4778574 is a positive allosteric modulation of *AMPA* receptor with EC₅₀ of 45 to 919 nM in differenct cells.

HY-103230

IEM-1460	iGluR	Neurological Disease
IEM-1460 blocks both *AMPA* and NMDA glutamate receptor with anticonvulsant effect in vivo .

HY-18663B

CP-465022 hydrochloride	iGluR	Neurological Disease
CP-465022 hydrochloride is a potent, and selective noncompetitive **AMPA receptor antagonist with anticonvulsant activity. CP-465022 is against Kainate-induced response with an IC₅₀** of 25 nM in rat cortical neurons. CP-465022 provides a new tool to investigate the role of AMPA receptors in physiological and pathophysiological processes .

HY-18663A

CP-465022 maleate	iGluR	Neurological Disease
CP-465022 Maleate is a potent, and selective noncompetitive **AMPA receptor antagonist with anticonvulsant activity. CP-465022 is against Kainate-induced response with an IC₅₀** of 25 nM in rat cortical neurons. CP-465022 provides a new tool to investigate the role of AMPA receptors in physiological and pathophysiological processes .

HY-18663

CP-465022	iGluR	Neurological Disease
CP-465022 is a potent, and selective noncompetitive **AMPA receptor antagonist with anticonvulsant activity. CP-465022 is against Kainate-induced response with an IC₅₀** of 25 nM in rat cortical neurons. CP-465022 provides a new tool to investigate the role of AMPA receptors in physiological and pathophysiological processes .

HY-15068

NBQX Maximum Cited Publications 10 Publications Verification FG9202	iGluR	Neurological Disease
NBQX (FG9202) is a highly selective and competitive **AMPA receptor** antagonist. NBQX has neuroprotective and anticonvulsant activity .

Cat. No.	Product Name	Target	Research Area

HY-P3340

Leptin (116-130)	iGluR	Neurological Disease
Leptin (116-130) is a bioactive leptin fragment. Leptin (116-130) promotes AMPA receptor trafficking to synapses and facilitate activity-dependent hippocampal synaptic plasticity. Leptin (116-130) prevents hippocampal synaptic disruption and neuronal cell death in models of amyloid toxicity. Leptin (116-130) has the potential for the research of Alzheimer's disease (AD) .

HY-P3355

p-fin4	iGluR	Neurological Disease
p-fin4 is a peptide inhibitor of STEP Phosphatase-GluA2 AMPA receptor interaction with a Ki of 0.4 μM. p-fin4 restores the memory deficits and displays anxiolytic and antidepressant effects in a scopolamine-treated rat model. p-fin4 is a promising lead compound for novel cognitive enhancers and/or behavioral modulators .

HY-P5487

GluR23Y	Peptides	Others
GluR23Y is a biological active peptide. (This GluR23Y peptide was used in ELISA cell-surface assay for the insulin-stimulated endocytosis of native AMPA receptors in cultured hippocampal neurons. GluR23Y prevented any insulin-induced reduction. The blockade of insulin action was observed when the GluR23Y peptide was delivered into neurons by fusing it to the membrane transduction domain of HIV-1.)

HY-P3354

p3Ysh-3	iGluR	Neurological Disease
p3Ysh-3 is a peptide inhibitor of STEP Phosphatase-GluA2 AMPA receptor interaction with a Ki of 1.09 μM. p3Ysh-3 restores the memory deficits and displays anxiolytic and antidepressant effects in a scopolamine-treated rat model. p3Ysh-3 is a promising lead compound for novel cognitive enhancers and/or behavioral modulators .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-14608

L-Glutamic acid Maximum Cited Publications 6 Publications Verification	Structural Classification Microorganisms Source classification Disease markers Endocrine diseases Amino acids Nervous System Disorder Endogenous metabolite Cardiovascular System Disorder Cancer	Endogenous Metabolite iGluR Ferroptosis Apoptosis
L-Glutamic acid is an excitatory amino acid neurotransmitter that acts as an agonist for all subtypes of glutamate receptors (metabolic rhodophylline, NMDA, and AMPA). L-Glutamic acid has an agonist effect on the release of DA from dopaminergic nerve endings. L-Glutamic acid can be used in the study of neurological diseases. L-Glutamic acid acts at ionotropic and metabotropic glutamate receptors .

HY-14608A

L-Glutamic acid monosodium salt Maximum Cited Publications 6 Publications Verification	Structural Classification Microorganisms other families Animals Source classification Amino acids Plants	iGluR Apoptosis Ferroptosis Endogenous Metabolite
L-Glutamic acid monosodium salt is an excitatory amino acid neurotransmitter that acts as an agonist for all subtypes of glutamate receptors (metabolic rhodophylline, NMDA, and AMPA). L-Glutamic acid monosodium salt has an agonist effect on the release of DA from dopaminergic nerve endings. L-Glutamic acid monosodium salt can be used in the study of neurological diseases. L-Glutamic acid monosodium salt acts at ionotropic and metabotropic glutamate receptors .

HY-116330A

Hyperforin dicyclohexylammonium salt 1 Publications Verification Hyperforin DCHA	Structural Classification Natural Products Guttiferae Source classification Hyperlcurn perforatum L. Plants	TRP Channel Calcium Channel
Hyperforin dicyclohexylammonium salt (Hyperforin DCHA) is a transient receptor canonical 6 (TRPC6) channels activator. Hyperforin dicyclohexylammonium salt modulates Ca ²⁺ levels by activating Ca ²⁺-conducting non-selective canonical TRPC6 channels. Hyperforin dicyclohexylammonium salt also shows diverse pharmacological activities including anti-depression, anti-tumor, anti-dementia, anti-diabetes. Hyperforin dicyclohexylammonium salt modulates γδ T cells to secret IL-17α, improves Imiquimod (HY-B0180)-induced psoriasis-like mice model .

HY-W015309

Decanoic acid	Structural Classification Microorganisms Neurological Disease Classification of Application Fields Ketones, Aldehydes, Acids Source classification Endogenous metabolite Disease Research Fields Biological Pesticide Research Agricultural Research	iGluR Tyrosinase c-Met/HGFR Glutaminase Endogenous Metabolite
Decanoic acid is a key component of the medium-chain triglyceride (MCT) found in coconut oil. Decanoic acid is a brain-penetrant and non-competitive inhibitor of *AMPA* receptor showing antiseizure activity in rats. Decanoic acid reduces tyrosinase activity and inhibits melanosome maturation. Decanoic acid suppresses the phosphorylation of c-Met and induced apoptosis in hepatocellular carcinoma (HCC) cells by inhibiting the expression of various oncogenic proteins, which is promising for research in the field of mTORC1 signaling, HCC and epilepsy .

HY-116330AR

Hyperforin dicyclohexylammonium salt (Standard)	Structural Classification Natural Products Guttiferae Source classification Hyperlcurn perforatum L. Plants	TRP Channel Calcium Channel
Hyperforin (dicyclohexylammonium salt) (Standard) is the analytical standard of Hyperforin (dicyclohexylammonium salt). This product is intended for research and analytical applications. Hyperforin dicyclohexylammonium salt (Hyperforin DCHA) is a transient receptor canonical 6 (TRPC6) channels activator. Hyperforin dicyclohexylammonium salt modulates Ca2+ levels by activating Ca2+-conducting non-selective canonical TRPC6 channels. Hyperforin dicyclohexylammonium salt also shows diverse pharmacological activities including anti-depression, anti-tumor, anti-dementia, anti-diabetes. Hyperforin dicyclohexylammonium salt modulates γδ T cells to secret IL-17α, improves Imiquimod (HY-B0180)-induced psoriasis-like mice model .

HY-14608AR

L-Glutamic acid (monosodium salt) (Standard)	Structural Classification Microorganisms other families Animals Source classification Amino acids Plants	iGluR Apoptosis Ferroptosis Endogenous Metabolite
L-Glutamic acid (monosodium salt) (Standard) is the analytical standard of L-Glutamic acid (monosodium salt). This product is intended for research and analytical applications. L-Glutamic acid monosodium salt is an excitatory amino acid neurotransmitter that acts as an agonist for all subtypes of glutamate receptors (metabolic rhodophylline, NMDA, and AMPA). L-Glutamic acid monosodium salt has an agonist effect on the release of DA from dopaminergic nerve endings. L-Glutamic acid monosodium salt can be used in the study of neurological diseases .

HY-W015309R

Decanoic acid (Standard)	Structural Classification Microorganisms Ketones, Aldehydes, Acids Source classification Endogenous metabolite	iGluR Tyrosinase c-Met/HGFR Glutaminase
Decanoic acid (Standard) is the analytical standard of Decanoic acid. This product is intended for research and analytical applications. Decanoic acid is a key component of the medium-chain triglyceride (MCT) found in coconut oil. Decanoic acid is a brain-penetrant and non-competitive inhibitor of AMPA receptor showing antiseizure activity in rats. Decanoic acid reduces tyrosinase activity and inhibits melanosome maturation. Decanoic acid suppresses the phosphorylation of c-Met and induced apoptosis in hepatocellular carcinoma (HCC) cells by inhibiting the expression of various oncogenic proteins, which is promising for research in the field of mTORC1 signaling, HCC and epilepsy .

HY-14608R

L-Glutamic acid (Standard)	Structural Classification Microorganisms Source classification Disease markers Endocrine diseases Amino acids Nervous System Disorder Endogenous metabolite Cardiovascular System Disorder Cancer	Endogenous Metabolite iGluR Ferroptosis Apoptosis
L-Glutamic acid (Standard) is the analytical standard of L-Glutamic acid. This product is intended for research and analytical applications. L-Glutamic acid is an excitatory amino acid neurotransmitter that acts as an agonist for all subtypes of glutamate receptors (metabolic rhodophylline, NMDA, and AMPA). L-Glutamic acid has an agonist effect on the release of DA from dopaminergic nerve endings. L-Glutamic acid can be used in the study of neurological diseases . IC₅₀ & Target:DA . In Vitro: L-Glutamic acid (120, 500, 750, 1000 mg/dL) can reduce the harmful effect of lithium on the embryonic development of Xenopus Xenopus . L-Glutamic acid (2, 5, 10, 20 mM, 24-48 h) can induce neuroexcitotoxicity in neuroblastoma . In Vivo: L-Glutamic acid (3 g/kg, subcutaneous injection) can promote excitotoxic degeneration of retinal ganglion cells in mice . L-Glutamic acid (750 mg/kg, intraperitoneal injection) can reduce and inhibit oxidative stress induced by chlorpyrifos (CPF) in rats .

Cat. No.	Product Name	Chemical Structure

HY-W015309S

Decanoic acid-d3
Decanoic acid-d₃ is the deuterium labeled Decanoic acid. Decanoic acid, a component of medium chain triclycerides, is a brain-penetrant and non-competitive inhibitor of AMPA receptor. Decanoic acid has antiseizure effects[1][2][3].

HY-W015309S1

Decanoic acid-d19
Decanoic acid-d₁₉9 is the deuterium labeled Decanoic acid. Decanoic acid, a component of medium chain triclycerides, is a brain-penetrant and non-competitive inhibitor of AMPA receptor. Decanoic acid has antiseizure effects[1][2][3].

HY-W015309S3

Decanoic acid-d5
Decanoic acid-d₅ is the deuterium labeled Decanoic acid. Decanoic acid, a component of medium chain triclycerides, is a brain-penetrant and non-competitive inhibitor of AMPA receptor. Decanoic acid has antiseizure effects[1][2][3].

HY-14608S7

L-Glutamic acid-d5
L-Glutamic acid-d₅ is the deuterium labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.

HY-14608S8

L-Glutamic acid-d3
L-Glutamic acid-d₃ is the deuterium labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.

HY-14608S5

L-Glutamic acid-13C5
L-Glutamic acid- ¹³C₅ is the ¹³C-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.

HY-14608S2

L-Glutamic acid-15N
L-Glutamic acid- ¹⁵N is the ¹⁵N-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals[1].

HY-W015309S2

Decanoic acid-d2
Decanoic acid-d₂ is the deuterium labeled Decanoic acid. Decanoic acid, a component of medium chain triclycerides, is a brain-penetrant and non-competitive inhibitor of AMPA receptor. Decanoic acid has antiseizure effects[1][2][3].

HY-10933S

CX516-d10
CX516-d₁₀ is the deuterium labeled CX516. CX516 (BDP 12) is an ampakine and acts as an AMPA receptor positive allosteric modulator for the research of Alzheimer's disease, schizophrenia and mild cognitive impairment (MCI)[1].

HY-14608S

L-Glutamic acid-13C
L-Glutamic acid- ¹³C is the ¹³C-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.

HY-14608S1

L-Glutamic acid-1-13C
L-Glutamic acid-1- ¹³C is the ¹³C-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.

HY-14608S6

L-Glutamic acid-5-13C
L-Glutamic acid-5- ¹³C is the ¹³C-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.

HY-14608S3

L-Glutamic acid-13C5,15N
L-Glutamic acid- ¹³C₅, ¹⁵N is the ¹³C- and ¹⁵N-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.

HY-14608S9

L-Glutamic acid-15N,d5
L-Glutamic acid- ¹⁵N,d₅ is the deuterium and ¹⁵N-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.

HY-14608S10

L-Glutamic acid-13C2
L-Glutamic acid- ¹³C₂ is the ¹³C labeled L-Glutamic acid[1]. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals[2].

HY-14608S4

L-Glutamic acid-13C5,15N,d5
L-Glutamic acid- ¹³C₅, ¹⁵N,d₅ is the deuterium, ¹³C-, and 15-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.

HY-B0122S

Topiramate-13C6

Topiramate-13C6 (McN 4853-13C6) is the ¹³C labeled isotope of Topiramate (HY-B0122). Topiramate (McN 4853) is a broad-spectrum antiepileptic agent. Topiramate is a GluR5 receptor antagonist. Topiramate produces its antiepileptic effects through enhancement of GABAergic activity, inhibition of kainate/AMPA receptors, inhibition of voltage-sensitive sodium and calcium channels, increases in potassium conductance, and inhibition of carbonic anhydrase .

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P82336

	*Phospho-Glutamate Receptor* 1 (AMPA Subtype) (Ser845) Antibody (YA2081)** GRIA1; GLUH1; GLUR1; Glutamate receptor 1; GluR-1; AMPA-selective glutamate receptor 1; GluR-A; GluR-K1; Glutamate receptor ionotropic; AMPA 1; GluA1	WB	Human, Rat
	Phospho-Glutamate Receptor 1 (AMPA Subtype) (Ser845) Antibody (YA2081) is a biotin-conjugated non-conjugated IgG antibody, targeting Phospho-Glutamate Receptor 1 (AMPA Subtype) (Ser845), with a predicted molecular weight of 102 kDa (observed band size: 102 kDa). Phospho-Glutamate Receptor 1 (AMPA Subtype) (Ser845) Antibody (YA2081) can be used for WB experiment in human, rat background.

HY-P81398

	Ionotropic Glutamate Receptor 2 Antibody (YA1143) GRIA2; GLUR2; Glutamate receptor 2; GluR-2; AMPA-selective glutamate receptor 2; GluR-B; GluR-K2; Glutamate receptor ionotropic; AMPA 2; GluA2	IHC-P	Human
	Ionotropic Glutamate Receptor 2 Antibody (YA1143) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1143), targeting Ionotropic Glutamate Receptor 2. Ionotropic Glutamate Receptor 2 Antibody (YA1143) can be used for IHC-P experiment in human background.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks